一圖看懂雍禾醫療(02279.HK)2021年度業績

2022年3月24日晚間,雍禾醫療(02279.HK)公佈截至2021年12月31日止年度業績,報吿顯示,受益於公司廣泛的全國醫療機構網絡,以及植髮醫療服務與醫療養固服務的整合,公司業務獲得了快速增長。集團收入同比增加32.4%至21.69億元;經調整純利同比增加32.8%至1.81億元,擬派末期股息每股人民幣0.076元。
截至2021年12月31日,公司在全國53個城市擁有54家醫療機構,為中國最大的及覆蓋城市最廣的連鎖植髮醫療集團。下面通過一圖形式展示公司2021年全年業績情況。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.